PT950100E - Mutantes do factor 2 de crescimento dos ceranocitos (fcc-2 ou factor 12 de crescimento dos fibroblastos fcf-12) - Google Patents

Mutantes do factor 2 de crescimento dos ceranocitos (fcc-2 ou factor 12 de crescimento dos fibroblastos fcf-12)

Info

Publication number
PT950100E
PT950100E PT97937200T PT97937200T PT950100E PT 950100 E PT950100 E PT 950100E PT 97937200 T PT97937200 T PT 97937200T PT 97937200 T PT97937200 T PT 97937200T PT 950100 E PT950100 E PT 950100E
Authority
PT
Portugal
Prior art keywords
growth factor
polynucleotides
polypeptides
relates
kgf
Prior art date
Application number
PT97937200T
Other languages
English (en)
Portuguese (pt)
Inventor
Steven M Ruben
Roxanne Duan
Pablo Jimenez
Mark A Rampy
Donna Mendrick
Jun Zhang
Jian Ni
Paul A Moore
Timothy A Coleman
Reiner L Gentz
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26697695&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT950100(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of PT950100E publication Critical patent/PT950100E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
PT97937200T 1996-08-13 1997-08-13 Mutantes do factor 2 de crescimento dos ceranocitos (fcc-2 ou factor 12 de crescimento dos fibroblastos fcf-12) PT950100E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2385296P 1996-08-13 1996-08-13
US3904597P 1997-02-28 1997-02-28

Publications (1)

Publication Number Publication Date
PT950100E true PT950100E (pt) 2004-06-30

Family

ID=26697695

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97937200T PT950100E (pt) 1996-08-13 1997-08-13 Mutantes do factor 2 de crescimento dos ceranocitos (fcc-2 ou factor 12 de crescimento dos fibroblastos fcf-12)

Country Status (13)

Country Link
EP (1) EP0950100B1 (cg-RX-API-DMAC7.html)
JP (1) JP2000517174A (cg-RX-API-DMAC7.html)
KR (1) KR20000029986A (cg-RX-API-DMAC7.html)
CN (1) CN1234071A (cg-RX-API-DMAC7.html)
AT (1) ATE259420T1 (cg-RX-API-DMAC7.html)
AU (1) AU739773B2 (cg-RX-API-DMAC7.html)
CA (1) CA2263143A1 (cg-RX-API-DMAC7.html)
DE (1) DE69727589T2 (cg-RX-API-DMAC7.html)
DK (1) DK0950100T3 (cg-RX-API-DMAC7.html)
ES (1) ES2212121T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ333725A (cg-RX-API-DMAC7.html)
PT (1) PT950100E (cg-RX-API-DMAC7.html)
WO (1) WO1998006844A1 (cg-RX-API-DMAC7.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6734285B2 (en) 1994-03-08 2004-05-11 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 proteins and compositions
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US6040157A (en) 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
DK0751992T3 (da) 1994-03-08 2006-03-06 Human Genome Sciences Inc Karendotelvækstfaktor 2
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US6077692A (en) 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US6693077B1 (en) 1995-02-14 2004-02-17 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US7232667B2 (en) 1995-02-14 2007-06-19 Human Genome Sciences, Inc. Keratinocyte growth factor-2 polynucleotides
AU775027C (en) * 1996-10-15 2005-12-08 Biovitrum Ab (Publ) Keratinocyte growth factor-2 products
DE69728415T2 (de) * 1996-10-15 2004-08-12 Amgen Inc., Thousand Oaks Produkte des keratinocyten-wachstumsfaktors 2 (kgf-2)
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
SI0935652T1 (en) * 1996-10-15 2004-06-30 Amgen Inc. Keratinocyte growth factor-2 products
US6869927B1 (en) 1997-12-22 2005-03-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
EP1041996A4 (en) * 1997-12-22 2003-05-14 Human Genome Sciences Inc KERATINOCYTE GROWTH FACTOR-2 FORMULATIONS
CN1295579A (zh) * 1998-02-13 2001-05-16 人类基因组科学公司 角质细胞生长因子2的治疗应用
JP2002505873A (ja) * 1998-03-13 2002-02-26 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 血管内皮増殖因子２
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
AU779787B2 (en) * 1999-05-14 2005-02-10 Curagen Corporation Secreted polypeptides and corresponding polynucleotides
AU5593200A (en) * 1999-06-02 2000-12-18 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
KR20020059609A (ko) 2000-08-04 2002-07-13 벤슨 로버트 에이치. 혈관 내피 성장 인자 ２
EP1357931A2 (en) * 2001-01-08 2003-11-05 Human Genome Sciences, Inc. Keratinocyte growth factor-2
JP2004536579A (ja) 2001-04-13 2004-12-09 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド 血管内皮増殖因子２
US7402312B2 (en) 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
US8871709B2 (en) * 2003-02-05 2014-10-28 Queensland University of Technolgy Synthetic chimeric proteins comprising epidermal growth factor and vitronectin
CN101780269A (zh) * 2009-01-21 2010-07-21 北京三有利科技发展有限公司 细胞生长因子治疗溃疡性疾病和肺纤维化疾病的应用
CN102438580B (zh) 2009-02-06 2015-06-17 加利福尼亚大学董事会 钙结合剂诱导毛发生长和/或甲生长
CN102727890A (zh) * 2012-07-05 2012-10-17 吉林农业大学 抗重组人角质细胞生长因子-2抗体的应用
US20160250298A1 (en) 2013-11-01 2016-09-01 Spherium Biomed S.L. Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents
CN104474533A (zh) * 2014-11-24 2015-04-01 华南理工大学 一种可用于创面修复的复合微球的制备方法
CN104593320B (zh) * 2015-01-04 2017-05-17 许永安 一种汗腺分化诱导培养基及其应用
US9597274B2 (en) * 2015-06-17 2017-03-21 Avon Products, Inc. Peptides and their use in the treatment of skin
CN109402130A (zh) * 2018-11-23 2019-03-01 成都中医药大学附属医院 一种重组人角质细胞生长因子-1及其制备方法和用途
CN111588837B (zh) * 2020-05-14 2023-06-06 中南大学湘雅三医院 一种蛋白-纳米银复合物的制备方法及制备的复合物和用途
KR102440312B1 (ko) * 2020-08-28 2022-09-05 한국해양과학기술원 온도안정성을 향상시킨 fgf7 폴리펩타이드 및 그 용도
CN112675294B (zh) * 2021-03-12 2021-05-14 诺赛联合(北京)生物医学科技有限公司 一种成纤维细胞的制备及在整形外科修复中的应用
WO2022204331A1 (en) * 2021-03-24 2022-09-29 Combangio, Inc. Compositions comprising branched kgf-2 derived peptides and methods for use in ocular treatment
EP4183796A1 (en) 2021-11-19 2023-05-24 Enantis s.r.o. Thermostable fgf10 polypeptide or fragment thereof use thereof
CN117736338A (zh) * 2023-12-08 2024-03-22 温州医科大学 一种角质细胞生长因子-透皮肽融合蛋白及其制备与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0815115T3 (da) * 1995-02-14 2003-09-15 Human Genome Sciences Inc Keratinocytvækstfaktor-2
DE69728415T2 (de) * 1996-10-15 2004-08-12 Amgen Inc., Thousand Oaks Produkte des keratinocyten-wachstumsfaktors 2 (kgf-2)

Also Published As

Publication number Publication date
DE69727589D1 (de) 2004-03-18
WO1998006844A1 (en) 1998-02-19
KR20000029986A (ko) 2000-05-25
DK0950100T3 (da) 2004-06-07
AU3977097A (en) 1998-03-06
CN1234071A (zh) 1999-11-03
ES2212121T3 (es) 2004-07-16
CA2263143A1 (en) 1998-02-19
NZ333725A (en) 2000-10-27
JP2000517174A (ja) 2000-12-26
ATE259420T1 (de) 2004-02-15
DE69727589T2 (de) 2004-08-05
AU739773B2 (en) 2001-10-18
EP0950100B1 (en) 2004-02-11
EP0950100A1 (en) 1999-10-20

Similar Documents

Publication Publication Date Title
DK0950100T3 (da) Keratinocytvækstfaktor-2- (KGF-2- eller fibroblastvækstfaktor-12-, FGF-12-) mutanter
WO2002077155A3 (en) Keratinocyte growth factor-2
DK0807633T3 (da) Hidtil ukendte 2,3-disubstituerede-(5,6)-heteroarylkondenserede pyrimidin-4-oner
BG107537A (bg) Инхибиране на човешка tnf алфа активност
EA199800268A1 (ru) Замещенные имидазолы, обладающие антиканцерогенной и цитокин-ингибирующей активностью
UA42747C2 (uk) Похідні пептиду,фармацевтична композиція та спосіб стимулювання секреції гормону росту
EA199700117A1 (ru) Трициклические бензазепиновые антагонисты вазопрессина, способ их получения, фармацевтическая композиция и способ лечения млекопитающих с использованием трициклических бензазепинов
ATE262899T1 (de) Substituierte (aryl, heteroaryl, arylmethyl oder heteroarylmethyl) hydroxamisaeureverbindungen
BG102999A (bg) Нови 2,3 дизаместени-4(3н)-хиназолинони
BRPI9917862B8 (pt) dihidropirimidinas, bem como processo para a preparação e aplicação das mesmas.
ES2063278T3 (es) Proteina morfogenetica de hueso.
DE69723728D1 (de) Totalsynthese des amino hip analogen von didemnin a
DE69840497D1 (de) Verwendung von Aplidine zur Behandlung von kardiovaskulären Erkrankungen
DE69130497D1 (de) Neue Verwendung von 1-Alpha-hydroxylierten-19-nor-vitamin-D-Verbindungen zur Behandlung von Psoriasis
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DE68909254D1 (de) Heparinbindende Gehirnmitogene.
ATE254472T1 (de) Hemmstoff für die gefässneubildung, der den gewebefaktor-inhibitor (tfpi) enthält
ATE151774T1 (de) Cyclopentanperhydrophenanthren-17-beta-(3-furyl - 3-derivate und pharmazeutische präparate davon, zur behandlung von kardiovaskulär-erkrankungen
DE68903907D1 (de) Cyclisches peptid, seine herstellung und seine verwendung zur behandlung von cardiovasculaeren stoerungen.
ATE114468T1 (de) Ethyl-(+)-apovincaminat zur behandlung der demyelinisierung klinischer erscheinungen autoimmunen ursprungs.
CO4910113A1 (es) Composiciones farmaceuticas estabilizadas, a base de quinu- pristina y de dalfopristina y su preparacion
DE69718500D1 (de) (-)-enantiomere von cis-3,4-chromanderivaten zur vorbeugung oder behandlungvon oestrogenbezogenen krankheiten oder syndromen
EP0826041A4 (en) Transforming growth factor alpha hii
AU4288285A (en) Novel pharmaceutical compositions having immuno-suppressive properties
ES2073919T3 (es) Derivados de piperidina 1,3,4-trisubstituidos, su obtencion y empleo.